The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2024 | MBL: biology, classification & the possibility of early interception
In this discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Paolo Ghia, MD, Vita Salute San Raffaele University, Milan, Italy, Andrew Rawstron, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, and Anton Langerak, PhD, Erasmus MC, Rotterdam, The Netherlands, discuss updates in the biology and classification of monoclonal B-cell lymphocytosis (MBL). The experts discuss differences between low- and high-count MBL, the role of the B-cell receptor, and comment on whether early interception is possible. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
